Sun Pharmaceutical Industries Ltd
SUNPHARMABSE 524715PharmaceuticalsMkt cap ₹4,34,269 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹15,300 Cr
YoY +10.5%QoQ +4.7%
Net profit · Q1 FY27
₹2,901 Cr
YoY +26.5%QoQ +7.1%
Net margin · Q1 FY27
19.0%
+2.4 pts vs Q1 FY26
Net profit · FY26
₹11,509 Cr
YoY +5.0%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 15,300 | 14,612 | 15,521 | 14,478 | 13,851 | +10.5% |
| Other income | 724 | 459 | 579 | 470 | 464 | +55.8% |
| Total income | 16,024 | 15,070 | 16,099 | 14,948 | 14,316 | +11.9% |
| Profit before tax | 4,099 | 3,551 | 4,227 | 4,168 | 3,173 | +29.2% |
| Tax | 1,188 | 828 | 826 | 1,031 | 870 | +36.5% |
| Net profit | 2,901 | 2,710 | 3,381 | 3,125 | 2,293 | +26.5% |
| Net margin | 19.0% | 18.5% | 21.8% | 21.6% | 16.6% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 58,462 | 52,578 | 48,497 | 43,886 | 38,654 | +11.2% |
| Other income | 1,972 | 1,965 | 1,354 | 635 | 922 | +0.3% |
| Total income | 60,434 | 54,543 | 49,851 | 44,520 | 39,576 | +10.8% |
| Profit before tax | 15,119 | 13,752 | 11,088 | 9,408 | 4,481 | +9.9% |
| Tax | 3,554 | 2,772 | 1,439 | 848 | 1,076 | +28.2% |
| Net profit | 11,509 | 10,965 | 9,610 | 8,513 | 3,389 | +5.0% |
| Net margin | 19.7% | 20.9% | 19.8% | 19.4% | 8.8% |
BIC's take
We haven't covered Sun Pharmaceutical Industries Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:50 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.